More Warnings Will Further Limit Quinolone Use

September 2018

Stronger warnings will lead to more concerns about quinolone risks.

Quinolone labels already caution about hypo- and hyperglycemia...and certain CNS effects such as agitation, nervousness, or confusion.

Now FDA will require warnings of hypoglycemic coma...especially in the elderly, renal impairment, or in combo with insulin or a sulfonylurea.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote